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Abstract. Cell contact with the extracellular matrix 
component hyaluronic acid (HA) plays an important 
role in many developmental, physiological, and patho- 
logical processes, although the regulation of this con- 
tact is poorly understood. CD44 proteins carry an 
amino acid motif that mediates affinity to HA. Artifi- 
cial clustering of the smallest 85-kD isoform of CD44 
(CD44s) has previously been shown to promote bind- 
ing of the protein to soluble HA (Lesley, J., R. Hyman, 
and P.W. Kincade. 1993. Adv. Immunol. 54:271-335; 
Persche, A., J. Lesley, N. English, I. Trowbridge, and 
R. Hyman. 1995. Eur. J. Immunol. 25:495-501). Here 
we show that in rat pancreatic carcinoma cells, splice 
variants of CD44 (CD44v), but not CD44s, form molec- 
ular aggregates in the plasma membrane. We demon- 
strate that reduction-sensitive dimerization of CD44v 
occurs, and also that larger aggregations of the protein 
can be stabilized by chemical cross-linking. Different 
CD44v proteins present on the same cell exclusively 
form homoaggregates. Molecular clustering does not 
require an intact cytoplasmic domain of the protein. 
The ability of cells to bind to soluble HA is upregulated 
more than one magnitude by the ectopic expression of 
CD44v4-v7, but only when the CD44v4-v7 protein forms 
intermolecular aggregates. Tunicamycin treatment in- 
hibits HA binding by CD44v and at the same time de- 
stroys oligomerization. We propose that the regulation 
of clustering of CD44, mediated by factors including 
the presence of variant exons and glycosylation, allows 
cells in turn to regulate their HA binding properties. 
I 
SOFORMS of the cell surface protein family CD44 have 
been implicated in a wide variety of physiological and 
pathological processes, such as T cell signaling and ac- 
tivation, lymphocyte recirculation, cell-cell and cell-matrix 
interactions, cell migration, embryogenesis, and metastasis 
(Herrlich  et  al.,  1993; Lesley et  al.,  1993; Knudson and 
Knudson, 1993; Sherman et al., 1994). The different CD44 
isoforms are generated by alternative splicing and/or by 
posttranslational modification (for review see Sherman et 
al., 1994). Most of the diversity is produced by the incorpo- 
ration of amino acid stretches encoded by ten alternatively 
spliced exons into one particular part of the extracellular 
portion of the CD44 proteins, close to the transmembrane 
domain. The most common and widely expressed 85-kD 
isoform  does  not  include  any  of  these  variant  exons 
(CD44s). Expression of variant isoforms of CD44 contain- 
ing sequences encoded by the variant exons (CD44v) is re- 
stricted mainly to a limited selection of epithelia in addi- 
tion to certain tumor cells (Heider et al., 1993). 
The CD44 isoforms CD44s and CD44v8-v10 have been 
shown to bind the extracellular matrix component hyal- 
uronate (HA)  1 (Aruffo et al., 1990; Dougherty et al., 1994). 
They  share  this  property  with  receptor  for  hyaluronic 
acid-mediated motility (RHAMM)  and intercellular ad- 
hesion molecule-1 (ICAM-1) (Hardwick et al., 1992; Mc- 
Court et al., 1994). Evidence for the HA receptor function 
of CD44s (for review see Lesley et al., 1993) includes the 
fact that the ectopic expression of CD44s in non-HA bind- 
ing cells can permit them to bind to HA, some anti-CD44 
antibodies can block the binding of HA to cell surfaces, 
and purified CD44s protein can bind to HA in vitro. CD44 
binds to a minimum of six HA sugar residues, but it has a 
higher affinity for larger HA molecules (Underhill et al., 
1993).  Molecular analysis of the binding of CD44 to HA 
identified an amino acid motif that is found twice in the 
extracellular  NH2-terminal  domain  shared  by  all  CD44 
proteins known to date. It occurs also in RHAMM and 
cartilage link protein (Yang et al., 1994). 
Expression  of CD44  on the  surface of cells does not 
oblige them to bind HA (Lesley et al., 1993). Furthermore, 
whether  the  HA  is  soluble  or  immobilized  affects the 
CD44-dependent  HA  binding  capacity  of different cell 
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bilized but not soluble HA (Lesley et al., 1993). The ability 
of CD44 on the cell surface to bind to HA can be experi- 
mentally and physiologically modified. Certain antibodies 
have  the  ability  to  stimulate  HA  binding  by otherwise 
nonbinding CD44 proteins on the surface of the cell. Stim- 
ulation of cells with phorbol esters can have a similar ef- 
fect (Lesley et al.,  1990; Liao et al.,  1993).  CD44 proteins 
thus  appear to exist in three states  with  respect to HA 
binding:  non-HA  binding;  nonbinding  unless  activated, 
e.g.,  by  antibodies  or physiological stimuli;  or constitu- 
tively binding (Lesley and Hyman, 1992).  The ability of 
CD44 to bind to HA appears to be regulated by its cellular 
environment, as transfection of the  same  CD44s  cDNA 
into  different  cell  lines  confers  HA  binding  properties 
onto some cell lines but not others (Lesley et al., 1993). 
The restricted expression of CD44 splice variants other 
than CD44s and their role in certain aggressive tumors in- 
dicate that these proteins possess molecular properties in 
addition to those exhibited by CD44s. The enormous di- 
versity of CD44 proteins generated by alternative splicing 
may function either to mediate binding to new ligands, or 
to  modulate  the  function  of domains  expressed  on  all 
CD44 proteins, such as the HA binding domain. Here we 
show that certain variant CD44 proteins can form multi- 
meric complexes in the plasma membrane, and that this 
dramatically enhances their HA binding capacity. 
Materials and Methods 
Cell Culture and Antibodies 
The hybridoma expressing the mAb 1.1ASML (Matzku et al., 1989),  the 
hybridoma OX50  (Paterson et al., 1987),  and derivatives of the BSp73 
pancreatic tumor cell lines (BSp73ASML [ASML], and BSp73AS clones 
10AS-7 [AS] and 1AS [Matzku et al., 1983l) were maintained in RPMI 
1640  medium  containing  10%  FCS.  The  AS  transfectants  ASpSV14 
(transfected  with  CD44v4-v7)  and  AS-meta2  (meta-2  now  denoted 
CD44v6,v7; Gtinthert et al., 1991; Rudy et al., 1993)  were maintained in 
RPMI 1640 medium containing 10% FCS, supplemented with 300 ~g/ml 
G418.  Antibodies were  purified  from  hybridoma-conditioned medium 
over protein G agarose (Harlow and Lane, 1988). 
Construction  of a Recombinant Retroviral  Vector  for 
Rat CD44v4-v7 Expression and Infection of 1AS Cells 
The eDNA of rat CD44v4-v7 (Giinthert et al., 1991)  was subcloned into 
the EcoRI site of pLXSN (Miller and Rosman, 1989), and the construct 
was transfected into fiE cells (Morgenstern and Land, 1990).  Producer 
cells were selected with G418, and conditioned medium containing recom- 
binant retrovirus was used to infect 1AS cells in the presence of 8 ixg/ml 
dimethrinebromide. After selection of G418-resistant clones, the expres- 
sion of CD44v4-v7 on  the surface of recipient  cells was confirmed by 
FACS  ® analysis. 
Construction of CD44 Meta-Stop Plasmid and 
Transfection  into AS Cells 
The pSVmetal plasmid (meta-1 now denoted CD44v4-v7; Gtinthert et al., 
1991) was cut with EcoRI and BglII to release the CD44v4-v7 insert. The 
insert was cut with HhaI to remove the cytoplasmic tail and the transmem- 
brahe domain. A synthetic linker with an HhaI site at the 5' end and en- 
coding the transmembrane domain, the three arginine residues immedi- 
ately COOH-terminal to lhe transmembrane domain, and a  stop codon 
were synthesized (MWG, Ebersberg, Germany). A BgllI site at the 3' end 
of this linker allowed the synthetic linker, the EcoRI-HhaI fragment en- 
coding the NH2 terminus of CD44v4-v7, and the original EcoRI/BgllI-cut 
vector to be ligated together. This created an expression plasmid encoding 
a CD44v4-v7 protein lacking the cytoplasmic tail, all except for the three 
arginine residues COOH-terminal to  the transmembrane domain. This 
construct (CD44 meta-stop) was cotransfected with pRSVneo (Gorman, 
1985)  into  AS  cells using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimeth- 
ylammonium methyl  sulfate  (DOTAP;  Boehringer  Mannheim, Mann- 
heim, Germany) according to the manufacturer's instructions. Transfec- 
tants were selected with 700 p~g/ml G418. Clones were picked and checked 
for CD44 meta-stop protein using the 1.1ASML antibody. 
Immunoprecipitation 
Cells were labeled with [35S]methionine (500 p,  Ci/ml) for 4 h in methio- 
nine-free RPMI supplemented with dialyzed FCS as described (Sleeman, 
1993). In Triton extractions, cells were incubated with 0.5% Triton X-100/ 
PBS on ice for 30 min, and then the nonsoluble material was pelleted by 
centrifugation at top speed in an Eppendorf centrifuge. The soluble super- 
natant was then diluted into 10-fold more RIPA buffer (150 mM NaCI, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5). 
The Triton-insoluble pellet was solubilizd in RIPA buffer. For pulse-chase 
analysis, cells were  incubated with [35S]methionine (500 I~Ci/ml)  for  15 
min in methionine-free RPMI supplemented with dialyzed FCS, and then 
washed and chased with methionine-containing medium. For cross-linking, 
radiolabeled cells were washed with PBS, and then treated with dithio- 
bis(succinimidylpropionate) (DSP) or dithiobis(sulfosnccinimidylpropionate) 
(Pierce, K61n, Germany) at 1 mg/ml in PBS for 1 h at room temperature. 
Unreacted cross-linker was quenched by incubation with 150 mM Tris, pH 
7.4, for 15 min. For immunoprecipitations, cells were lysed in RIPA buffer 
and aliquots were immunoprecipitated with 5  p~g antibody as described 
(Sleeman, 1993).  Immunoprecipitated proteins were separated by SDS- 
PAGE. Gels were treated with diphenyloxazole, as described (Sleeman, 
1993) and exposed to x-ray film. 
Surface Iodination 
107 cells were resuspended in 200 ixl PBS and mixed with 0.5 mCi ~2SNaI 
and 10 ~1 lactoperoxidase (1 p,g/ml).  10 txl H202 solution (diluted 1:10,000, 
1:3,000,  and 1:1,000 in PBS, respectively) was then added three times at 
1-min intervals. The reaction was stopped by washing the cells three times 
in ice-cold PBS containing 5 mM NaI. 
SDS-PAGE and Western Blotting 
Proteins were resolved by size (Laemmli, 1970) using a resolving gel con- 
taining 7% polyacrylamide. For two-dimensional gel analysis, the first di- 
mension was run in tube gels under nonreducing conditions, The tube gels 
were then incubated in reducing sample buffer for 1 h and affixed to the 
second dimension using 1% agarose containing 125 mM Tris, pH 6.8, and 
2% SDS. For Western blotting, proteins separated by SDS-PAGE were 
electrically  transferred  to  nitrocellulose  (Schleicher  &  Schuell, Dassel, 
Germany) by the method of Towbin et al. (1979). Filters were washed in 
TBS for 10 min, and then used or stored frozen at  -20°C. Blots were 
probed  with  antibody  using  the  ECL  detection  system  (Amersham, 
Braunschweig, Germany) as previously described (Sleeman, 1993). 
HA Binding Assays 
Coulter counter cups (Sarstedt,  Heidelberg,  Germany) were incubated 
overnight with 0.5 ml of 1 mg/ml HA in PBS, or with PBS alone for con- 
trols. After washing with PBS, the cups were incubated with 2  ml PBSI 
10%  FCS  for  30  min.  Cells  were  harvested with  PBS/5  mM EDTA, 
counted, and radiolabeled by incubation with [35S]methionine in methio- 
nine-free medium. Where indicated, labeled cells were treated with DTI" 
(10 mM in PBS) at room temperature for 5 min, immediately before addi- 
tion to the Coulter counter cups. Tunicamycin (Sigma, Diesenhofen, Ger- 
many) was added to cells as appropriate at 7.5 ixg/ml 36 h before labeling 
commenced, and tunicamycin was also included in the medium during the 
labeling incubation. The cells were washed with PBS, and then 5  ×  10  s 
cells were added to each Coulter counter cup in 0.5 ml PBS/10% FCS and 
incubated at room temperature for 30 min. After washing the cups three 
times with PBS, bound cells were lysed with PBS/0.5% Triton X-100, and 
the number of cells bound was calculated from quantification of radiola- 
bel in the lysate. Each sample was performed in triplicate. 
Flow Cytometry 
Cells were harvested with 5 mM EDTA/PBS  and resuspended in PBS/ 
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HA was at 10 ~g/ml. After incubation for 30 rain, the cells were washed 
with PBS  and incubated for an additional  30 min with fluorescently la- 
beled secondary antibody (for antibody staining) or streptavidin (for HA 
staining).  The  cells  were  washed  with  PBS,  and  then  analyzed  by  a 
FACS®tar Plus Flow Cytometer (Becton Dickinson & Co., Mountain View, 
CA). As negative controls, cells were stained with either isotype-matched 
control antibodies or with no primary antibody. No difference in staining 
was observed between these two controls. 
Results 
Hyaluronate Binding Function of CD44 Proteins 
We investigated the HA binding properties of an number 
of cell lines derived from the BSp73 pancreatic carcinoma 
with respect to CD44  expression (see Table I). None of 
these cell lines express significant levels of RHAMM or 
ICAM-1 (data not shown). BSp73 clone 10AS-7 rat pan- 
creatic carcinoma cells (hereafter called AS cells) express 
the  CD44s isoform at high levels (G0nthert et al.,  1991) 
but bind poorly to soluble HA, while AS cells transfected 
with  a  CD44v4-v7 construct  (ASpSV14;  Gtinthert  et al., 
1991)  bind avidly to soluble HA in a  CD44v4-v7-depen- 
dent  manner  (Fig.  1;  Sleeman  et  al.,  1996).  However, a 
clone of the BSp73AS cell line called 1AS (Matzku et al., 
1983) did not support soluble HA binding even after trans- 
fection with CD44v4-v7 (Fig. 1; data not shown). Thus, a 
stable CD44v4-v7 transfectant of 1AS cells called 1ASm7, 
although expressing slightly more CD44v4-v7 on their sur- 
face than ASpSV14 cells, nevertheless binds very poorly to 
soluble  HA, unlike  ASpSV14  cells (Fig.  1).  Clearly, the 
binding of CD44 to HA in these cell lines is regulated by 
factors other than mere expression of CD44 protein. Simi- 
lar observations have been made in other cell types (e.g., 
Lesley et al., 1993; Moll, J., S. Khaldoianidi, J. Sleeman, I. 
Preuss,  H. Ponta,  and P.  Herrlich, manuscript submitted 
for publication).  Thus, the data in Fig.  1 raise two ques- 
tions.  What  molecular  difference  between  CD44s  and 
CD44v4-v7  determines  their  differing  ability  to  bind  to 
HA? What makes CD44v4-v7 in one clone of AS cells a 
high-affinity soluble HA binder, while in another clone it 
is virtually a nonbinder? 
Structural Requirements for HA Binding 
Evidence for a role of CD44 protein structure in HA bind- 
ing came from a comparison of binding of CD44 to either 
soluble or immobilized HA. Binding to immobilized HA 
has been considered  a  less stringent  test of HA binding 
Table L Properties of  BSp73 Pancreatic Carcinoma Cell Lines 
and Their Transfectants 
Cell line  Parental cell line  Endogenous  CD44  Transfected  CD44 
10AS-7 (AS)  -  CD44s 
1AS  -  CD44s  - 
ASML  -  CD44s, multiple  - 
CD44v 
ASpSV 14  10AS  CD44s  CD44sv4-v7 
1  ASm7  I AS  CD44s  CD44sv4-v7 
AS-meta2  10AS  CD44s  CD44sv6-v7 
M4.2  10AS  CD44s  CD44sv6-v7, without 
cytoplasmic tail 
so  lo,¢sl 
0~01  ~  I0 1 "'-']02  ...... i0 $  ....  104 
loAs/ 
sO 
0 
ASpSV14  / e^ 
4 
s0]0..  I~i  1ASML,~,LASm7/  so  t 
i00  i0 1  ...... 103  ..... l0 s  ...... i~ 4  01/l 
1ASm7/ 
Figure 1.  Binding of 10AS, ASpSV14, and 1ASm7 cells to solu- 
ble HA in  relation to their expression  of CD44v4-v7. FACS  ® 
analysis was performed as described in Materials and Methods on 
cells stained with 1.1ASML or with biotinylated HA. Plots of fluo- 
rescence intensity (abscissa, log scale) against cell number (ordi- 
nate, linear scale) are shown. In each case, the open trace repre- 
sents background staining, while the filled-in trace represents the 
staining with the indicated reagent. 
than binding to soluble HA, as several cell lines bind to 
immobilized but not to soluble HA (l_esley et al.,  1993). 
ASpSV14 cells also bind to immobilized HA better than 
AS  cells  (Fig.  2  A).  The  1ASm7  transfectant  similarly 
shows binding ability that is higher than the parental 1AS 
cell line, although it still binds considerably less well to im- 
mobilized HA than ASpSV14 (Fig. 2 A). A possible expla- 
nation  of these  results is that the immobilization of HA 
enforces or facilitates CD44 proteins to adopt a conforma- 
tional property, which they do not always acquire sponta- 
neously (Lesley et al., 1993). 
Although the amino acid motif permitting HA binding 
is linear (Yang et al., 1994), CD44 is predicted to take up 
a higher order structure based on disulphide bridges (Gold- 
stein et al., 1989; Neame et al., 1986). Furthermore, CD44 is 
heavily glycosylated by AS cells, most of which is N-linked 
(Rudy et al., 1993). This glycosylation must also influence 
the three-dimensional structure of the protein. To deter- 
mine whether the protein structure imposed by the disul- 
phide  bridges  and  N-linked  glycosylation contributes  to 
HA binding,  we  treated  AS-derived  cells  with  DTI" or 
with tunicamycin and looked at the effect on their ability 
to bind HA. The presence of DTT abolished the binding 
to both immobilized and soluble HA (Fig. 2, B and C). In- 
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Figure 2.  (A) The binding of 10AS, ASpSV14, 1AS, and 1ASm7 
cells to immobilized HA. Cells were radiolabeled and applied to 
HA-coated (/HA) or mock-coated (/PBS) Coulter counter cups 
(5  x  105 cells  per cup). Nonadherent cells were washed away. 
Percentage of cell adhesion was calculated with reference to the 
total radioactivity in 5  x  105 labeled cells  by lysing the bound 
cells and by counting the radiactivity in the lysate.  (B) The effect 
of tunicamycin and DTF on the ability of ASpSV14 and 1ASm7 
cells to bind to HA immobilized on Coulter counter cups. The ex- 
periment was performed as described in Fig. 2 A. Cells were ei- 
ther mock treated, treated with 7.5 p.g/ml tunicamycin for 36 h 
hibition of N-linked glycosylation by tunicamycin also dra- 
matically reduced the ability of ASpSV14 cells to bind to 
immobilized  or soluble  HA  (Fig.  2,  B  and  C).  Further- 
more, tunicamycin treatment of 1ASm7 ceils reduced their 
ability to bind immobilized HA (Fig. 2 B). Treatment with 
DTF or with tunicamycin did not diminish CD44 expres- 
sion on the cell surface, but in fact slightly enhanced its ex- 
pression  (data  not shown).  Cell  viability was maintained 
throughout these experiments.  We conclude that the HA 
binding properties of CD44 proteins depend on secondary 
or higher order structure that is sensitive to reduction and 
changes in glycosylation. 
CD44v Proteins Can Homodimerize 
The data in Fig. 2 suggested that CD44 protein conforma- 
tion is altered by reduction, and that this destroys its abil- 
ity to bind to HA. We therefore looked at the effect of re- 
duction on the migration properties  of CD44 proteins in 
SDS-PAGE to attempt to relate reduction-sensitive struc- 
tures in CD44 proteins with HA binding capacity. In the 
absence of a  reducing agent,  a  proportion of CD44v4-v7 
protein  from  ASpSV14  cells  migrated  in  both  Western 
blot  and  immunoprecipitation/SDS-PAGE  analyses  at  a 
higher apparent molecular weight (~280,000), in addition 
to the 140-kD form normally detected under reducing con- 
ditions (Fig. 3). This higher molecular weight form was de- 
tected  by  both  a  CD44v6-specific  antibody  (1.1ASML) 
and  by  a  CD44  antibody  that  binds  to  an  extracellular 
epitope  common to all  CD44 proteins  (OX50).  A  single 
higher molecular weight form was observed in 1.1ASML 
immunoprecipitations, while three bands migrating closely 
together were obtained with OX50 (Fig. 3 A). These were 
completely extracted by treatment of the cells with Triton 
X-100, suggesting that the higher molecular weight forms 
were not associated with the underlying cytoskeleton (Fig. 
3 A). In similar experiments in which CD44s protein from 
AS cells was analysed using the OX-50 antibody, no higher 
molecular weight complexes were observed (Figs. 3 A  and 
4 B; data not shown). 
Other  CD44 isoforms from different cell contexts  also 
exhibit this reduction-sensitive  complex formation. Meta- 
static BSp73ASML cells (hereafter called ASML cells) ex- 
press a number of different CD44 variant proteins includ- 
ing  CD44v4-v7  and  CD44v6-v7  as  the  major  isoforms. 
CD44v6-containing proteins from ASML cells were analy- 
sed along with CD44v6-v7 protein from the AS transfec- 
tant cell line AS-meta-2 (Gtinthert et al., 1991; Rudy et al., 
1993)  (Fig. 3 B).  In the case of ASML, a  smear of high 
molecular weight proteins (300,000-350,000) reactive with 
before the experiment (TUN), or treated with 10 mM DTI" im- 
mediately  before  being  applied  to  the  Coulter  counter  cups 
(DTT). (C) The effect of tunicamycin and DTF on the ability of 
ASpSV14 cells to bind to soluble HA. FACS  ® analysis  was per- 
formed as described in Materials  and Methods on cells stained 
with biotinylated HA. Plots of fluorescence intensity (abscissa, 
log scale)  against cell number (ordinate, linear scale) are shown. 
The control cells (Cont.) demonstrate the background staining. 
The binding of ASpSV14 cells to HA is shown, along with ceils 
treated with 7.5  ~g/ml tunicamycin for 36 h  before the experi- 
ment (HA~TUN), and cells incubated with 10 mM DTr for 15 
min immediately before the addition of HA (HA/DTT). 
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CD44v4-v7 from ASpSV14 cells on SDS-PAGE under reducing 
and  nonreducing  conditions.  Both  OX-50  (pan  CD44)  and 
1.1ASML  (v6-specific)  antibodies  precipitate  higher  molecular 
weight forms of CD44v4-v7 under nonreducing conditions (ar- 
row). Radiolabeled cells were extracted with 0.5% Triton, and all 
higher molecular weight forms precipitated from total extract (T) 
are found only in the soluble phase (S) and not in the Triton in- 
soluble pellet (P). The lane marked CONTROL is an OX-50 im- 
munoprecipitate of the AS cells from which the ASpSV14 trans- 
fectant  cell  line  is  derived.  Molecular  weight  markers  are 
indicated (kD). (B) Detection of higher molecular weight forms 
of CD44v in  ASML, ASpSV14, and  AS-meta2  (Meta-2)  ceils. 
Cell lysates were prepared in SDS-PAGE sample buffer with and 
without  DTT.  Western  blots  of the  lysates  were  probed  with 
1.1ASML antibody.  The  monomeric forms of CD44v4-v7 and 
CD44v6-v7 are on the left (arrows)  for ASML, and on the right 
(arrows)  for  CD44v4-v7 from  ASpSV14 cells  and  CD44v6-v7 
from AS-meta2 cells,  respectively. It should be  noted  that the 
monomeric forms in ASML cells migrate differently to those in 
transfected AS cells, due to differences in glycosylation (Rudy et 
al.,  1993). The apparent presence of CD44v4-v7 in lysates from 
AS-meta2 cells treated with DTT is due to spill-over from the ad- 
jacent ASpSV14 lysate.  The position of molecular weight mark- 
ers is shown (kD). 
1.1ASML antibody was detected in the absence of reduc- 
ing reagent, in addition to the CD44 isoforms detected un- 
der reducing conditions. With AS transfectants expressing 
CD44v6-v7, one additional band was observed at 230 kD 
under nonreducing conditions,  in addition  to the  ll5-kD 
form also detected under reducing conditions. 
Figure 4.  Nonreducing/reducing two-dimensional gel analysis  of 
1.1ASML and OX50 immunoprecipitates from radiolabeled ly- 
sates from ASpSV14 cells. Immunoprecipitates were resolved in 
a 7% nonreducing tube gel in the first dimension. After incuba- 
tion of the  tube  gel with reducing sample  buffer, the  proteins 
within the tube gel were run into and resolved on a 7% second di- 
mension gel. CD44s immunoprecipitated by OX50 is designated 
with  an  arrow,  as  is  CD44v4-v7 immunoprecipitated  by  both 
1.IASML and OX50 (v4-v7).  Only CD44v4-v7 immunoprecipi- 
tates  exhibit  reduction-sensitive  dimerization  (arrows  beneath 
each panel). Molecular weight markers are shown (kD). 
One  explanation  for the  occurrence of high  molecular 
weight CD44v-containing aggregates would be that CD44v 
proteins can interact with other molecules (potential ligands) 
in a  reduction-sensitive manner.  We investigated whether 
proteins other than CD44v are present in the high molecu- 
lar  weight  moieties  detected  under  nonreducing  con- 
ditions.  Radiolabeled  proteins  from ASpSV14 cells  were 
immunoprecipitated  with  the  CD44v6-specific  antibody 
1.1ASML or with the pan-CD44 specific OX50 antibody. 
The immunoprecipitates were analyzed by two-dimensional 
gel electrophoresis  in which the  first  dimension  was run 
under  nonreducing conditions  and the  second dimension 
under reducing conditions. This allowed the resolution of 
the 280- and  140-kD forms of CD44v4-v7 in the first  di- 
mension, and the subsequent disruption by reduction and 
analysis of the 280-kD form in the second dimension. Fig. 
4 shows that the nonreduced 280-kD form immunoprecipi- 
tated  by both antibodies  resolves  at  140 kD  after  reduc- 
tion,  and  that  no  other  labeled  proteins  are  contained 
within the complex. 1.1ASML staining of Western blots of 
gels  from  similar  two  dimensional  analyses  using  unla- 
beled proteins  showed that the resolved protein complex 
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shown).  No CD44s-CD44v heterodimers were observed, 
and  no CD44s  homodimers were  detected by the  OX50 
immunoprecipitation (Fig. 4 B). These data are consistent 
with the hypothesis that the high molecular weight forms 
observed under nonreducing  conditions  are homodimers 
of CD44v  proteins.  The  fact  that  the  higher  molecular 
weight forms of CD44v4-v7 and CD44v6-v7 detected un- 
der nonreducing conditions are exactly twice the molecu- 
lar weight of the form detected under reducing conditions 
lends further support to this hypothesis. 
Pulse-chase  analysis showed  that  dimer formation oc- 
curs late after CD44v synthesis, when the protein is fully 
glycosylated.  ASpSV14  cells  were  pulsed  with  [35S]me- 
thionine for 15 min, and then a chase was performed with 
unlabeled methionine. At different times cells were lysed, 
and the CD44v4-v7 protein was irnmunoprecipitated with 
1.1ASML. Immunoprecipitated proteins were analyzed by 
SDS-PAGE under nonreducing conditions. Fig. 5 A shows 
that immediately after the pulse, CD44v4-v7 protein mi- 
grates at a lower apparent molecular weight than the ma- 
ture form because it is first labeled within the cell in an un- 
derglycosylated form (Lokeshwar and Bourguignon, 1991; 
Rudy et al.,  1993).  As the  chase progressed, the  protein 
became fully glycosylated. However, dimers of CD44v4-v7 
did not appear in the chase until 1 h  after the pulse, at a 
time  when  the  CD44  protein  is  fully  glycosylated  and 
would be expected to already be on the cell surface. Fur- 
Figure 5.  (A) Pulse-chase  analysis of the formation of dimers by 
CD44v4-v7 in ASpSV14 cells. Cells were pulsed for 15 min, and 
then chased for 0.5, 1, 2, 4, and 8 h. After lysis in RIPA buffer, the 
radiolabeled proteins were immunoprecipitated with  1.1ASML 
and analyzed by SDS-PAGE under nonreducing  conditions. Mo- 
lecular weight markers are indicated  (kD). (B) Surface iodination 
of ASpSV14 cells. After surface iodination,  ASpSV14 cells were 
lysed in RIPA buffer and immunoprecipitated with 1.1ASML an- 
tibody. Immnnoprecipitates were taken up in sample buffer with 
and without DT/" and resolved on by 7% SDS PAGE. Molecular 
weight markers are indicated  (kD). 
ther evidence for dimer formation on the cell surface was 
obtained by surface iodination. Fig. 5 B shows that dimers 
of CD44v4-v7  are readily immunoprecipitated from sur- 
face-iodinated ASpSV14  cells, and that these  dimers are 
reduction sensitive. These data show that the formation of 
dimers of CD44v is a late event after synthesis and glyco- 
sylation of the protein, and that dimers are located on the 
surface of the cell. 
Chemical Cross-linking Reveals Higher Order 
Oligomers of CD44v Proteins 
CD44v  protein  could  either  form  dimers  via  a  specific 
dimerization domain or through multivalent interactions. 
The latter is more likely, as evidence for clusters of CD44v 
protein containing multiple molecules of CD44v4-v7 was 
obtained from cross-linking studies. ASpSV14 cells were 
radiolabeled, and then treated with cross-linking reagents. 
The  cells  were  subsequently  lysed  and  immunoprecipi- 
tated with  1.1ASML.  Immunoprecipitates were analyzed 
by SDS-PAGE,  A  number of cross-linking reagents were 
tested. After treatment with one of these, DSP, lysates of 
ASpSV14 cells contained complexes containing CD44v4- 
v7 of much higher molecular weight than CD44v4-v7 mono- 
mers and dimers. (Fig. 6 A; bands with arrows Xand Y). 
The cross-linker DSP contains a  disulphide bridge that 
can be broken by reducing reagents. We could therefore 
investigate  the  constituent  parts  of  the  high  molecular 
weight CD44v4-v7-containing complexes (X and Y) pro- 
duced by DSP cross-linking. First, the two complexes and 
CD44v4-v7 monomeric protein were cut out of the gel. The 
proteins were isolated, reduced, and resolved on another 
SDS-PAGE gel. Fig. 6 B shows that the protein in the high 
molecular weight complexes resolves at exactly the same 
molecular weight  as  the  monomeric CD44v4-v7 protein, 
and that no additional labeled proteins could be detected. 
Secondly,  1.1ASML immunoprecipitates of lysates made 
from radiolabeled, DSP-cross-linked ASpSV14 cells were 
analyzed  on  two-dimensional  gels.  The  first  dimension 
was run under nonreducing conditions to allow the resolu- 
tion  of the  high  molecular weight  complexes containing 
CD44v4-v7, while the second dimension was run under re- 
ducing conditions to reverse the cross-linking, allowing vi- 
sualization of the components of the complexes. Fig. 6  C 
shows that both complexes migrate at the same apparent 
molecular weight  as monomeric CD44v4-v7 upon reduc- 
tion, and that no additional proteins are found within the 
complexes. These data suggest that DSP cross-linking sta- 
bilizes homooligomers of CD44v4-v7. The chemical cross- 
linker dithiobis(sulfosuccinimidylpropionate), which is water 
soluble and cannot cross plasma membranes, showed the 
same CD44v cross-linking capacity as DSP (data not shown), 
indicating that the stabilization of oligomers occurs on the 
cell surface, and that oligomerization is a property of CD44v 
proteins in the plasma membrane. 
We  conclude  from  these  data  that  CD44v4-v7  forms 
dimers and oligomeric clusters in the plasma membrane of 
AS cells, while CD44s does not. 
CD44v Preferentially Form Homooligomers 
Although  CD44s is coexpressed with  CD44v4-v7 on the 
surface of ASpSV14 cells, heterooligomerization was not 
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viously to precipitate the endogenous CD44s protein. The 
immunoprecipitate was subjected to two-dimensional non- 
reducing/reducing gel electrophoresis as described before. 
Fig. 7 A  shows that no higher order oligomers of CD44s 
were observed after DSP cross-linking of AS cells. This sug- 
gests that at least in AS ceils, CD44s does not participate 
in oligomer formation, consistent with the observation that no 
reduction-sensitive dimers of CD44s were detected in AS cells. 
ASML cells coexpress two major forms of CD44v (120- 
and  150-kD)  and  two  minor  forms  (180-  and  195-kD), 
each  of which  contains  sequences  encoded  by  exon  v6 
(Giinthert et al., 1991; see Fig. 3 B). Thus, by radiolabeling 
these cells, cross-linking them with DSP, and subsequently 
immunoprecipitating their proteins with 1.1ASML antibody, 
it should be possible  to differentiate  between  homo- and 
heterooligomerization  of CD44v  proteins  in  two-dimen- 
sional  nonreducing/reducing  gel  analysis.  In  the  second, 
reducing dimension,  the constituent  parts of heterooligo- 
mers should resolve as spots lying along a vertical line. Ho- 
mooligomers, on the other hand, should resolve as single 
Figure 6.  (A) High order oligomers of CD44v4-v7 are detected 
by cross-linking.  Radiolabeled ASpSV14 cells were treated with 
0, 100, 250, 500, and 1,000 txg/ml DSP, lysed in RIPA buffer, and 
immunoprecipitated  with  1.1ASML.  Immunoprecipitates  were 
analyzed  by  5%  SDS-PAGE.  The  migrations  of monomeric, 
dimeric,  and  high  molecular  weight  complexes  X  and  Y  of 
CD44v4-v7 are designated with arrows. Molecular weight mark- 
ers are indicated (kD). (B) Monomeric CD44v4-v7 and the high 
molecular weight complexes X and Y in Fig.  6 A  were excised 
from the gel,  incubated with reducing sample buffer, and sub- 
jected to SDS-PAGE in a 5-20% polyacrylamide gradient. When 
reduced,  complexes  X  and  Y  migrate  at  the  same  molecular 
weight  as  monomeric  CD44v4-v7.  No  additional  comigrating 
bands from complexes X and Y are observed. The migration of 
molecular weight markers  is indicated  (kD).  (C) Nonreducing/ 
reducing two-dimensional gel analysis  of 1.1ASML immunopre- 
cipitates from a lysate of radiolabeled ASpsV14 cells cross-linked 
with 1 mg/ml DSP. Under reducing conditions, the high molecu- 
lar  weight complexes X  and  Y  resolve  at  the  same  molecular 
weight as monomeric CD44v4-v7 (see arrows X  and Y). The mi- 
gration of molecular weight markers is indicated (kD). 
observed between  these two proteins  in the cross-linking 
studies described above (Fig. 6 C). This suggested, on the one 
hand, that CD44s may not participate in oligomer formation, 
and, on the other hand, that CD44v may preferentially form 
homooligomers. Both of these possibilites were investigated. 
AS cells  were  labeled,  cross-linked  with  DSP,  and im- 
Figure 7.  (A) Nonreducing/reducing two-dimensional gel analy- 
sis of radiolabeled lysates from AS cells cross-linked  with 1 mg/ml 
DSP and immunoprecipitated by OX50. No high molecular com- 
plexes of CD44s can be detected. (B) Nonreducing/reducing two- 
dimensional gel analysis of radiolabeled lysates from ASML cells 
cross-linked  with  1  mg/ml  DSP  and  immunoprecipitated  by 
1.1ASML. The two major CD44v6-containing proteins in ASML 
cells  (v6-v7 and  v4-v7)  are indicated.  The resolution  of cross- 
linked  high molecular complexes of these  proteins  into mono- 
mers under reducing conditions is indicated by arrows beneath 
the panel. 
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mers, then the single spots corresponding to the reduced, 
monomeric form of CD44v protein should lie along a diag- 
onal line. Fig. 7 B shows that the oligomeric forms of the 
two major CD44v6-containing proteins in ASML cells re- 
solve as  single spots  after reduction and  migrate  at  the 
same molecular weight as the corresponding monomeric 
forms. The two spots lie along a  diagonal line. No other 
spots lie vertically above or below them, showing them to 
be resolved from homooligomers. No resolved spots could 
be  detected  for the  minor  CD44v6-containing  proteins, 
perhaps due to insufficient sensitivity in the experiment or 
lack of oligomer formation by these isoforms. These re- 
suits suggest that in ASML cells that coexpress multiple 
CD44v isoforms, homooligomers rather than heterooligo- 
mers are preferentially formed. 
Our  experiments, in  which reducing agents  destroyed 
CD44v-dependent soluble HA binding, linked soluble HA 
binding with  reduction-sensitive structures in  the  CD44 
molecule. By analyzing reduction-sensitive structural prop- 
erties of CD44,  we  discovered CD44v  homodimers  and 
homooligomers. It therefore remained for us to determine 
whether this molecular association influences soluble HA 
binding by CD44v. 
Oligomer Formation Correlates with Soluble HA 
Binding by CD44v4-v7 
CD44v proteins molecularly associate when expressed in 
AS cells, while CD44s proteins do not. This clustering thus 
correlates directly with the  affinity for soluble HA con- 
ferred by CD44v on AS cells. CD44v4-v7 expression con- 
fers negligible soluble HA binding activity on 1ASm7 cells. 
If the clustering of CD44v influences its ability to bind sol- 
uble HA, then CD44v4-v7 from 1ASm7 cells should not be 
expected to form dimers or oligomers. The analysis of clus- 
tering  of CD44v4-v7  in  the  1ASm7  cell  line  proved to 
strongly support a role for clustering in soluble HA binding. 
1ASm7  cells  were  analyzed  for  the  ability  of  their 
CD44v4-v7 protein to form dimers  and  oligomers using 
the  same  methods described previously. Fig.  8 A  shows 
that CD44v4-v7 does not form dimers when expressed on 
the surface of 1ASm7 cells, unlike ASpSV14 cells. Simi- 
larly, CD44v4-v7 on 1ASm7 cells is not cross-linked into 
higher  order  oligomers,  unlike  CD44v4-v7  protein  ex- 
pressed on ASpSV14 cells (Fig. 8 B). These data correlate 
the molecular association of CD44v with its ability to bind 
to soluble HA and strongly suggest that soluble HA bind- 
ing by CD44v is dependent on the ability of the protein to 
molecularly aggregate on the cell surface. 
The Cytoplasmic  Tail Is Not Required for HA Binding 
or  for Dimer and Oligomer Formation by CD44v4-v7 
Several studies report that the cytoplasmic tail of CD44 in- 
teracts with components of the cytoskeleton (for review 
see Isacke, 1994) and that the absence of a cytoplasmic tail 
can  reduce the  ability of CD44s  protein to bind to HA 
(Thomas et al., 1992; Lesley and Hyman, 1992; Lesley et al., 
1993; Liao et al.,  1993). These reports prompted us to in- 
vestigate whether the cytoplasmic tail influences the affinity 
of CD44v4-v7 for soluble HA and the ability of CD44v4-v7 
to form homodimers and homooligomers. 
Figure 8.  Nonreducing/reducing  two-dimensional gel analysis of 
radiolabeled  lysates  from  1ASm7cells immunoprecipitated  by 
1.1ASML, with and without cross-linking of the ceils with 1 mg/ml 
DSP before lysis. No high molecular weight complexes can be de- 
tected. Molecular weight markers are indicated (kD). 
We constructed a tail-less CD44v4-v7 expression vector 
(CD44 meta-stop) that lacks all but the first three amino 
acids of the cytoplasmic tail. This was transfected into AS 
cells, which do not bind to soluble HA (Fig. 1; Sleeman et al., 
1996).  A  stable transfectant (M4.2) expressing the CD44 
meta-stop  protein  at  levels  similar  to  the  full-length 
CD44v4-v7 protein in ASpSV14 cells was identified using 
the  1.1ASML antibody.  Surprisingly, the  M4.2  transfec- 
tant bound to soluble HA as efficiently as the ASpSV14 
cells (Fig. 9 A). However, consistent with our contention 
that  aggregation  of CD44  promotes  binding  to  soluble 
HA,  the  tail-less  CD44v4-v7 mutant  protein  from M4.2 
cells also forms both dimers and homooligomers (Fig 9 B). 
This shows that the cytoplasmic tail plays no role in the 
molecular homointeraction of CD44v  proteins,  and  fur- 
ther  suggests  that  dimer  and  oligomer  formation  by 
CD44v suffices to prevent the inhibitory effect of cytoplas- 
mic tail truncation on soluble HA binding that has previ- 
ously been reported for CD44s (Thomas et al.,  1992; Les- 
ley and Hyman, 1992; Lesley et al., 1993; Liao et al., 1993). 
Glycosylation, a Prerequisite of Oligomerization and 
HA Binding 
Inhibition  of  N-linked  sugar  addition  by  tunicamycin 
treatment reduced both the immobilized and soluble HA 
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Using the previously described reducing/nonreducing two- 
dimensional gel analysis, we found that the partially degly- 
cosylated form and the completely non-N-linked glycosy- 
lated  form of CD44v4-v7  are  only weakly able  to  form 
dimers, visible only after long exposure of the gel. More- 
over, neither  the partially deglycosylated nor the non- 
N-linked glycosylated form are able to form cross-linkable 
oligomers (Fig. 10).  This result shows that changes in gly- 
cosylation can influence the ability of CD44v4-v7 to oligo- 
merize and provides further evidence that oligomerization 
enhances the HA binding capacity of CD44v4-v7. 
Figure 9.  (A) HA binding by ASpSV14 and M4.2 cells to soluble 
HA in relation to their expression of CD44v4-v7. Plots of fluores- 
cence intensity (abscissa, log scale) against cell number (ordinate, 
linear scale)  are shown. In each case, the open trace represents 
background staining, while the filled-in trace represents the stain- 
ing with the indicated  reagent. (B) Nonreducing/reducing  two- 
dimensional  gel analysis of radiolabeled lysates from M4.2 cells, 
either nontreated or cross-linked  with  lmg/ml DSP before lysis 
and immunoprecipitated by 1.1ASML. In both cases, high molec- 
ular weight complexes can readily be detected (arrows). 
binding  mediated  by CD44v4-v7  in  AS  cells  (Fig.  2,  B 
and  C). Furthermore,  completion of the  glycosylation of 
CD44v4-v7 preceded oligomer formation (Fig. 5 B). This 
prompted  us  to  investigate  whether  one  mechanism  by 
which tunicamycin treatment interferes with HA binding 
could be the inhibition of cluster formation by CD44v4-v7. 
As  demonstrated  by  Rudy  et  al.  (1993),  treatment  of 
ASpSV14 cells with tunicamycin only completely inhibits 
the  addition  of N-linked sugars in  a  small proportion of 
the  CD44v4-v7 protein  (labeled ng in Fig.  10), while the 
Figure  10.  The  effect  of  tunicamycin  on  the  formation  of 
CD44v4-v7 dimers and oligomers.  ASpSV14  cells were treated 
with 7.5 p,g/ml tunicamycin  for 36 h before the experiment, and 
after radiolabeling  were either nontreated  or cross-linked  with 
lmg/ml DSP before lysis. Lysates of these cells were immunopre- 
cipitated with  1.1ASML and analyzed  by nonreducing/reducing 
two-dimensional  gel analysis. The righthand side panels show re- 
ducing SDS-PAGE analysis of 1.1ASML immunoprecipitates of 
radiolabeled ASpSV14 cells treated with and without tunicamy- 
cin (+  and  -  Tun)  to indicate  the efficacy of the tunicamycin 
treatment.  The  non-N-glycosylated  (ng)  form  of  CD44v4-v7 
weakly forms dimers (arrow beneath the panel) but does not form 
oligomers. Molecular weight markers (kD) are shown. 
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Our experiments provide evidence for the modulation of 
the HA binding ability of CD44 proteins at several levels. 
HA  binding  mediated  through the  NH2-terminal amino 
acid motifs is determined by a reduction-sensitive protein 
structure, by the variant exon-promoted clustering of the 
protein in the plane of the plasma membrane and by gly- 
cosylation, which  in  turn  is  required  for the  oligomeric 
clustering. Given these results, we propose that the much 
higher, soluble HA binding capacity of CD44v compared 
with CD44s on AS cells that we have previously reported 
(Sleeman et al., 1996; Fig. 1) can be explained by the clus- 
tering of CD44v. Cellular regulation of the molecular asso- 
ciation of CD44 proteins, e.g., by alternative splicing and 
specific glycosylation, likely provides plasticity in the bind- 
ing response of cells to the extracellular matrix, allowing 
them to respond appropriately to different biological situ- 
ations. 
Oligomeric clustering in rat pancreatic carcinoma cells 
of the larger CD44 splice variants in contrast with CD44s 
is one of the key results of this paper. We interpret the re- 
duction-sensitive high molecular weight forms of CD44v 
as  evidence for homodimer formation. Several observa- 
tions  argue  against  alternative  interpretations.  The  fact 
that the higher molecular weight forms of CD44v are ex- 
actly double  the  monomeric forms in  each case speaks 
strongly in favor of dimer formation, as well as against an 
interaction of CD44v proteins with another putative mole- 
cule that, for whatever reason, failed to be radiolabeled in 
the two-dimensional gel analyses; interaction with such a 
unitary molecule would not double the size of each CD44v 
protein. The appearance of a triplet of higher molecular 
weight forms of CD44v4-v7 observed with OX50 but not 
1.1ASML (Fig. 3 A) probably reflects steric effects affect- 
ing 1.1ASML antibody access to the dimeric proteins in as- 
sociation with conformational changes in the CD44 pro- 
tein after dimer formation. 
Only  a  minor proportion of the  total  CD44v  present 
forms multimers. However, this fraction of the total is ex- 
tremely important for HA binding. This observation has 
parallels with  ligand  binding by integrins  (Dustin et al., 
1989;  Diamond  and  Springer,  1993).  The  relatively low 
yield of cross-linked higher order oligomers of CD44v4-v7 
is probably due to only a small window where cross-link- 
ing of specifically interacting proteins occurs, before such 
complexes themselves are  cross-linked into an insoluble 
pellet, as the cell essentially becomes fixed by the cross- 
linking  reagent.  This  effect is  readily seen  in  Fig.  6 A, 
where increasingly less monomeric CD44v4-v7 protein is 
available for immunoprecipitation as the concentration of 
cross-linker  increases.  From  the  experiments  presented 
here,  it is  not  possible  to  ascertain  whether dimers  are 
building blocks for the formation of oligomers. 
The ability of CD44v proteins to oligomerize correlates 
well with their affinity for soluble HA. The link is sup- 
ported by three lines of evidence. First, there is a coordi- 
nated lack of soluble HA binding and CD44v oligomeriza- 
tion  in  the  mutant  cell  line  1ASm7.  Secondly,  CD44v 
protein lacking a cytoplasmic tail forms oligomeric com- 
plexes and binds to soluble HA, in contrast with truncated 
CD44s protein that can do neither. Thirdly, tunicamycin 
treatment inhibits both soluble HA binding and oligomer 
formation. 
This paper focuses on  the  characterization of CD44v 
multimerization and its relationship to soluble HA binding 
in pancreatic carcinoma cells. The observation that CD44v 
forms multimers while CD44s does not is unlikely to be a 
general rule for all cells. A  clear prediction would be that 
CD44s is able to spontaneously oligomerize in cell lines 
that support soluble HA binding in a  CD44s-dependent 
manner. 
Numerous findings by other laboratories indirectly sup- 
port the notion that clustering of CD44 protein promotes 
its ability to bind to soluble HA. Certain antibodies can ac- 
tivate HA binding by CD44s, which at least in AS cells 
does  not  cluster  spontaneously.  These  antibodies  only 
work when binding multivalently (Lesley et al., 1993). Fur- 
thermore,  chimerization  of the  extracellular  portion  of 
CD44s with the transmembrane region of the CD3 ~ chain 
caused enforced dimerization of the fusion protein via di- 
sulphide links between CD3 ~ chains, as well as enhanced 
HA binding (Perschl et al., 1995). Immobilized HA may in 
part facilitate clustering of the receptors (see also Lesley et 
al., 1993). Thus, CD44s can be bellied to duster and to bind 
soluble HA, as CD44v expressed on AS cells does sponta- 
neously. 
Several groups have shown that the presence of CD44 
on the cell surface does not oblige cells to bind to HA (see 
Lesley et al.,  1993; Moll, J., S. Khaldoiani, J. Sleeman, I. 
Preuss, H. Ponta, and P. Herrlich, manuscript submitted 
for publication). We propose which CD44 proteins which 
cannot form stable clusters require additional help to bind 
HA, be it in the form of cross-linking "activating" antibod- 
ies or by the immobilization of the HA to stabilize weak 
CD44-CD44  or  CD44-HA  interactions.  This  proposal 
would also explain the observation that surface levels of 
CD44 have to be above a threshold level before efficient 
HA binding occurs (He et al.,  1992); higher surface levels 
of CD44 would promote intermolecular association. 
Although we have clearly demonstrated here that CD44v 
forms aggregates on the cell surface, the nature of the pro- 
tein-protein interaction remains unclear. Dimerization is 
reduction sensitive. While one could argue that intramo- 
lecular disulphide links may hold CD44 proteins in a con- 
formation that allows them to dimerize via noncovalent in- 
teractions even after boiling in 2% SDS, a more attractive 
possibility is that dimers of CD44 are formed as a result of 
intermolecular disulphide bridges. None of the variant ex- 
ons v4-v7 encode cysteine residues, ruling out disulphide 
links between the variant portions of the CD44v proteins 
analyzed in  this  study.  Interestingly, DTT treatment  of 
ASpSV14 cells, a cell line whose soluble HA binding ca- 
pacity is due to transfected CD44v4-v7, ablates their abil- 
ity to bind to soluble HA, demonstrating that disulphide 
bonds are required for HA binding. Again, this could be 
interpreted as indicating a  functional role for intramo- 
lecular loops (as proposed for the HA binding domain of 
cartilage link protein [Goldstein et al., 1989; Neame et al., 
1986]) or for intermolecular disulphide bridges. The incor- 
poration of variant domains into a CD44 protein may alter 
its conformation such that a  secondary structure needed 
for clustering is formed or that intermolecular disulphide 
bonding can occur. In both cases, the exact distance of the 
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variant exon sequences could enforce exclusive homooli- 
gomerization. 
Truncation of the cytoplasmic portion of CD44s reduces 
the HA binding efficiency of the protein (Thomas et al., 
1992; Lesley and Hyman, 1992; Lesley et al., 1993; Liao et al., 
1993),  but the truncated protein retains the ability to be 
activated to bind soluble HA by certain activating anti- 
CD44 antibodies (Lesley and Hyman, 1992). Disruption of 
the cytoskeleton does not interfere with HA binding by 
CD44 (Murakami et al., 1994), suggesting that the reduced 
binding capacity of cytoplasmically truncated CD44 pro- 
tein may be due to reasons other than ablation of CD44- 
cytoskeletal interactions. Here we show that a truncated 
CD44v4-v7 (CD44 meta-stop) protein mediates binding to 
soluble HA perfectly well when transfected into AS cells, 
and that the  CD44  meta-stop protein forms dimers and 
oligomers. We therefore conclude that clustering of CD44 
overrides the need for a cytoplasmic tail to allow soluble 
HA binding, a conclusion consistent with the observation 
of Lesley and Hyman (1992)  that a truncated CD44 pro- 
tein can still be stimulated to bind HA by certain anti-CD44 
antibodies, which would couple the protein into dimers. 
We  have  shown  here  by  tunicamycin  inhibition  that 
N-linked glycosylation is essential for the oligomerization 
and HA binding capacity of CD44. The fact that CD44v is 
hyperglycosylated with respect to CD44s in the BSp73AS 
system (Giinthert et a1.,1991; Rudy et a1.,1993) may there- 
fore be  pertinent to the lack of soluble HA binding by 
CD44s in AS cells. Differences in glycosylation between 
clustered and nonclustered CD44v proteins are not neces- 
sarily extensive, however, as the CD44v4-v7 protein from 
ASpSV14 cells, which binds soluble HA efficiently and has 
the capacity to cluster, migrates similarly on SDS-PAGE 
as CD44v4-v7 protein from 1ASm7 cells, which does not 
cluster or bind soluble HA (data not shown). Highly spe- 
cific tunicamycin-sensitive modifications may determine 
both CD44 clustering and HA binding, as the binding of 
both ASpSV14 and 1ASm7 to immobilized HA is also in- 
hibited by tunicamycin treatment. 
Changes in N-linked glycosylation and glycosaminogly- 
can addition influence HA binding by CD44 in other sys- 
tems (Katoh et al., 1995; Lesley et al., 1995). In these stud- 
ies, tunicamycin treatment upregulated HA binding. We 
have also found cell lines whose HA binding capacity is 
upregulated  by  tunicamycin  (Moll,  J.,  unpublished  re- 
suits). However, in agreement with the results presented 
in this paper, another study recently showed that tunica- 
mycin treatment of a  panel of cell lines abrogated their 
HA  binding capacity  (Bartolazzi  et  al.,  1996).  Further- 
more,  this  study showed that mutation of the  N-linked 
sugar sites on CD44 destroyed the capacity of the CD44 
protein to confer HA binding properties when expressed 
in non-HA-binding melanoma cells, clearly demonstrating 
the  requirement  for N-linked  sugars  in  CD44-mediated 
HA binding. The  diverse  effects of tunicamycin under- 
score the complexity of the regulation of HA binding by 
CD44. We suggest that perhaps differences in the site of 
addition and constituence of the  N-linked  sugars  may 
differentially influence the HA binding ability of CD44 
proteins. This is supported by our observation that short 
times of exposure to tunicamycin slightly upregulate HA 
binding in ASpSV14  cells (Sleeman, J., unpublished re- 
suits), suggesting that the extent of inhibition of N-linked 
sugar addition by tunicamycin may be critical. For exam- 
ple, even long exposures to tunicamycin that downregulate 
HA binding do not completely inhibit addition of all of 
the N-linked sugars (Fig. 10). Additionally, carbohydrate 
groups  that are  not influenced by tunicamycin may be- 
come more important in determining oligomerization and 
HA binding levels after tunicamycin treatment. For exam- 
ple, CD44v4-v7 when expressed on AS cells also has O-linked 
carbohydrate (Rudy et al., 1993). O-linked sugars recently 
have been shown to inhibit HA binding (Bennett et al., 
1995). Different cell lines may add a different complement 
of carbohydrates onto the CD44 protein, in turn affecting 
the ability of the protein to cluster and/or to bind to HA, 
permitting regulation of the HA binding activity of the 
CD44 protein. 
In summary, this and other studies are consistent with a 
model in which aggregation of CD44 molecules on the cell 
surface enhances their HA binding properties. This molec- 
ular association is regulated by the cell to control its ability 
to bind HA in the extracellular matrix. Changes in glyco- 
sylation may be instrumental in this regulation. What is 
true for HA binding by CD44 may also be true for its abil- 
ity to bind to other ligands, potentially opening a whole ar- 
ray of regulation to control the function of the CD44 pro- 
tein family. 
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